The Efficacy and Safety of Concurrent Collagenase Clostridium Histolyticum Injections for 2 Dupuytren Contractures in the Same Hand: A Prospective, Multicenter Study.

Autor:	Gaston RG; OrthoCarolina, Inc., Charlotte, NC. Electronic address: glenn.gaston@orthocarolina.com., Larsen SE; Unit for Hand Surgery, Department of Orthopaedics, Odense University Hospital, Odense, Denmark., Pess GM; Central Jersey Hand Surgery, Eatontown, NJ., Coleman S; Brisbane Hand and Upper Limb Clinic, Brisbane, Queensland, Australia., Dean B; Auxilium Pharmaceuticals, Inc., Chesterbrook, PA., Cohen BM; Auxilium Pharmaceuticals, Inc., Chesterbrook, PA., Kaufman GJ; Auxilium Pharmaceuticals, Inc., Chesterbrook, PA., Tursi JP; Auxilium Pharmaceuticals, Inc., Chesterbrook, PA., Hurst LC; Stony Brook University Medical Center, Stony Brook, NY.
Jazyk:	angličtina
Zdroj:	The Journal of hand surgery [J Hand Surg Am] 2015 Oct; Vol. 40 (10), pp. 1963-71. Date of Electronic Publication: 2015 Jul 26.
DOI:	10.1016/j.jhsa.2015.06.099
Abstrakt:	Purpose: To evaluate efficacy and safety of concurrent administration of 2 collagenase clostridium histolyticum (CCH) injections to treat 2 joints in the same hand with Dupuytren fixed flexion contractures (FFCs). Methods: Patients with 2 or more contractures in the same hand caused by palpable cords participated in a 60-day, multicenter, open-label, phase 3b study. Two 0.58 mg CCH doses were injected into 1 or 2 cords in the same hand (1 injection per affected joint) during the same visit. Finger extension was performed approximately 24, 48, or 72 or more hours later. Changes in FFC and range of motion, incidence of clinical success (FFC ≤ 5°), and adverse events (AEs) were summarized. Results: The study enrolled 715 patients (725 treated joint pairs), and 714 patients (724 joint pairs) were analyzed for efficacy. At day 31, mean total FFC (sum of 2 treated joints) decreased 74%, from 98° to 27°. Mean total range of motion increased from 90° to 156°. The incidence of clinical success was 65% in metacarpophalangeal joints and 29% in proximal interphalangeal joints. Most treatment-related AEs were mild to moderate, resolving without intervention; the most common were swelling of treated extremity, contusion, and pain in extremity. The incidence of skin lacerations was 22% (160 of 715). Efficacy and safety were similar regardless of time to finger extension. Conclusions: Collagenase clostridium histolyticum can be used to effectively treat 2 affected joints concurrently without a greater risk of AEs than treatment of a single joint, with the exception of skin laceration. The incidence of clinical success in this study after 1 injection per joint was comparable to phase 3 study results after 3 or more injections per joint. Two concurrent CCH injections may allow more rapid overall treatment of multiple affected joints, and the ability to vary the time between CCH injection and finger extension may allow physicians and patients greater flexibility with scheduling treatment. (Copyright © 2015 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu